Negative in Ames, in vitro chromosome aberration and rat bone marrow micronucleus assays
“BHV-3000 was negative in Ames, chromosomal aberration, and rat bone marrow micronucleus assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 58Source ↗
Carcinogenicity
26-week Tg.rasH2 mouse and 2-year rat: no drug-induced tumors
“Based on a review by the CDER Division of Biometrics, BHV-3000 did not induce tumor formation in the 26-week and 2-year carcinogenicity studies in TgRasH2 mice (0, 30, 100 300 mg/kg) and SD rats (0, 5, 15, 45 mg/kg), respectively.”
✓ VerifiedFDA pharmacology/toxicology review, p. 58Source ↗
Reproductive & developmental
Rat fertility: uterine atrophy >25 mg/kg, reduced conception at 150 mg/kg; no embryofetal toxicity in rat or rabbit
“Two fertility studies in SD rat indicated uterine atrophy at doses greater than 25 mg/kg, and decreased conception and increased pre-implantation loss at 150 mg/kg. There was no embryofetal toxicity in rat or rabbit.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Safety pharmacology
No CNS, cardiovascular or respiratory effects; hERG and sodium channel IC50 >30 µM
“There were no effects of BHV-3000 on CNS, cardiovascular, or respiratory safety pharmacology endpoints, and the IC50 for hERG or sodium ion channels was estimated to be in excess of 30 uM.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative